Maximize your Study’s Potential: How Expert Recommendations on Data Collection, Data Flow, Standards and AI can Transform Outcomes

In the past decade, clinical trials have embraced new innovations, including digital technologies like wearables, eCOA, and eSource. These advancements generate vast amounts of data, necessitating robust data ecosystems for streamlined processes and efficient utilization of artificial intelligence within study execution. IQVIA’s experts play a crucial role in recommending standards and strategies to achieve these goals, resulting in accelerated study start-up and improved data transparency.

Register Free:
https://www.appliedclinicaltrialsonline.com/act/study-potential

Event overview

Over the last 5 to 10 years, opportunities to include new innovations within clinical trials have increased dramatically. We see new data collection options to shift data collection closer to the patient with the use of digital technologies like wearables, eCOA and eSource. These new data sources can produce millions of additional datapoints, which require standard automated data flow solutions, connected to digital downstream processes. With the increased focus on artificial intelligence, it is necessary to rely on a robust data ecosystem that can handle all clinical and operational data to ensure streamlined data flow and operational processes.

The variety of options and capabilities can be overwhelming for a study team. In this session, we will demonstrate how IQVIA’s team of Digital Transformation Experts, Data Strategists and Standards Engineers review the protocol to recommend the standards, data collection and data flow strategies needed to automate and fully utilize artificial intelligence within study processes, and how those recommendations are put into practice once the study begins.

Starting with a strong study strategy, coming from IQVIA’s experts, the study execution can run smoothly, ensuring accelerated study start-up and database lock, while increasing data transparency to make faster study decisions.

Three key take-aways

• Realize the potential of how a comprehensive study strategy aligns expectations to the operational study plans and maximizes benefits of technology and artificial intelligence within a data flow.
• Understand the new roles of technology and how these apply to new study strategy opportunities.
• How to optimize study strategy by applying the right mix of comprehensive standards, E2E data flow and data collection.

Speakers:

Christina Larsen
Director of Innovation, Data Sciences, Safety and Medical
IQVIA

Christina serves as a director for the Innovation team of IQVIA’s Data Sciences, Safety and Medical division. In this role, she leads the standardization, simplification and digitization of data management, biostatistics and medical processes to transform the business, providing insight and guidance into IQVIA’s next-generation unified data and process platforms. Christina has over 20 years’ experience in the industry, across programming, data management, statistics and risk-based monitoring, and has worked both domestically and internationally within the large pharma, CRO, and technology spaces. Christina graduated with a Bachelor of Arts degree in Mathematics, Cum Laude from Boston University and is a certified IQVIA Lean Practitioner.

Register Free:
https://www.appliedclinicaltrialsonline.com/act/study-potential